Breathe Well Live Well
Condition: Asthma
Interventions: Drug: MK-1029 150 mg; Drug: Placebo for MK-1029; Drug: Montelukast 10 mg; Drug: Albuterol/Salbutamol 90 mcg – 100 mcg per inhalation
Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting – verified March 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Intervention: Drug: Montelukast 10 mg orally
Sponsor: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
Recruiting – verified December 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Montelukast: A Review of Recent Studies in Pediatric Asthma and Allergic Rhinitis
Medscape Montelukast was approved by the Food and Drug Administration (FDA) on February 20, 1998 for the treatment of asthma in children and adults. It has gained widespread acceptance as an adjunct to inhaled corticosteroids and beta-adrenergic agonists in the … |
View full post on asthma – Google News
Condition: Respiratory Disorders
Interventions: Drug: Reference Montelukast; Drug: Test 1 Montelukast; Drug: Test 2 Montelukast
Sponsor: GlaxoSmithKline
Not yet recruiting – verified December 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Montelukast 5 mg chewable tablets; Drug: Montelukast 5 mg chewable tablets
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed – verified May 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Montelukast versus inhaled corticosteroids in the management of pediatric mild …
7thSpace Interactive (press release) International guidelines recommend the use of inhaled corticosteroids (ICSs) as the preferred therapy, with leukotriene receptor antagonists (LTRAs) as an alternative, for the management of persistent asthma in children. Montelukast (MLK) is the first … |
View full post on asthma – Google News
 AccentedTouch |
Asthma and Allergy Patients Prescribed Montelukast Instead of First Line …
AccentedTouch “Patients with asthma or allergic rhinitis (nasal allergies), initially prescribed montelukast (Singulair) instead of typical first-line therapy have low rates of persistence on montelukast and may ultimately discontinue therapy altogether, … |
View full post on asthma – Google News
|
Patients with asthma or allergies initially prescribed montelukast instead of …
pharmabiz.com Patients with asthma or allergic rhinitis (nasal allergies), initially prescribed montelukast (Singulair) instead of typical first-line therapy have low rates of persistence on montelukast and may ultimately discontinue therapy altogether, according to … |
View full post on asthma – Google News
|
Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for …
PR Newswire (press release) Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis. … |
View full post on asthma – Google News
|
Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for …
SYS-CON Media (press release) Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis. … |
View full post on asthma – Google News